Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 7/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422761 | 0.84 | CCR2 (0.46) | CCR2KCNH2CASP3CTSK | |
| SCHEMBL4417131 | 0.81 | CASP3 (0.53) | CASP3CASP1CTSKPREPALDH1A1 | |
| SCHEMBL5030646 | 0.80 | CCR2 (0.42) | CCR2KCNH2CASP3CTSKALDH1A1 | |
| SCHEMBL14313644 | 0.80 | CASP3 (0.50) | CASP3CASP1CTSKPREPALDH1A1 | |
| SCHEMBL4416820 | 0.80 | CCR2 (0.47) | CCR2KCNH2CTSK | |
| SCHEMBL4416824 | 0.80 | CCR2 (0.47) | CCR2KCNH2CTSK | |
| SCHEMBL14313605 | 0.79 | CASP3 (0.50) | CASP3CASP1CTSKPREPALDH1A1 | |
| SCHEMBL4413483 | 0.79 | CCR2 (0.46) | CCR2KCNH2CASP3CTSKALDH1A1 | |
| SCHEMBL4413487 | 0.79 | CCR2 (0.46) | CCR2KCNH2CASP3CTSKALDH1A1 | |
| SCHEMBL3739167 | 0.78 | CCR2 (0.45) | CCR2KCNH2CASP3CTSKPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005079519-A2 | SUBSTITUTED BICYCLOALKYLAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |